Compare VFS & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFS | TLX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Vietnam | Australia |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 3.3B |
| IPO Year | 2022 | 2024 |
| Metric | VFS | TLX |
|---|---|---|
| Price | $2.57 | $8.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $5.57 | ★ $19.66 |
| AVG Volume (30 Days) | ★ 453.1K | 281.5K |
| Earning Date | 12-02-2026 | 02-18-2027 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $40.12 | $16.83 |
| Revenue Next Year | $48.91 | $13.81 |
| P/E Ratio | ★ N/A | $150.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.67 | $6.28 |
| 52 Week High | $5.29 | $13.11 |
| Indicator | VFS | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 28.20 | 33.74 |
| Support Level | N/A | $6.28 |
| Resistance Level | $3.28 | $9.83 |
| Average True Range (ATR) | 0.13 | 0.25 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 5.42 | 0.95 |
VinFast Auto Ltd manufactures cars, and motor vehicles, renders leasing activities, trades smartphones, and related businesses. The company is engaged in designing and manufacturing premium EVs, e-scooters, and e-buses. The company's initial EV product line is an all-new range of fully electric A- through E-segment SUVs. The Company has three reportable segments, namely Car, E-scooter and Ebus. The Car segment includes the design, development, manufacturing and sales of cars and related battery lease and battery charging services for cars. The E-scooter segment includes the design, development, manufacturing and sales of e-scooters and related battery lease and battery charging service for e-scooters. The Ebus segment includes the design, development, manufacturing and sales of Ebus.
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.